Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Subscribe To Our Newsletter & Stay Updated